Printer Friendly

Medizone International announces successful results from AsepticSure disinfection system's trial held at Ontario's QHC Belleville General Hospital.

M2 PHARMA-February 15, 2013-Medizone International announces successful results from AsepticSure disinfection system's trial held at Ontario's QHC Belleville General Hospital(C)2013 M2 COMMUNICATIONS

Medizone International (MZEI:OB) revealed on Thursday that its AsepticSure system has passed the safety and preliminary operational trials conducted at the Quinte Health Care Belleville General Hospital, an affiliation of Queen's University.

In partnership with Contamination Control Company (C3) of Canada, Medizone has unequivocally demonstrated the safety and ease of operation of its AsepticSure disinfection process in a functioning health care setting. Room turnaround times were less than 90 minutes.

According to Dr Michael E Shannon, Medizone's director of Medical Affairs, Quinte Health Care has an excellent HAI record and to demonstrate success at one of their busy, acute community hospitals is extremely encouraging. The introduction of AsepticSure into the healthcare industry will be seen as a breakthrough that could lead to hospitals achieving levels of infection prevention and control not considered possible, until now.

AsepticSure will be establishing a new gold standard in the continuing quest for excellence in patient safety and quality health care, which is supported by the great ease-of-use and compatibility that the system demonstrated at QHC Belleville General Hospital, added Dr Shannon.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Feb 15, 2013
Words:213
Previous Article:Aetna names Nancy Ham as CEO of Medicity.
Next Article:Rosetta Genomics Ltd awarded two key US patent allowances for additional viral microRNAs diagnostic products.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters